利用突触囊泡糖蛋白2A正电子发射断层成像评估阿尔茨海默病中的突触密度
这项横断面研究纳入10例阿尔茨海默病(AD)患者和11例认知正常者,采用11C-UCB-J PET成像检测海马突触囊泡糖蛋白2A(SV2A)结合。AD患者海马SV2A特异性结合较认知正常者降低41%,校正萎缩后仍显著,且与情景记忆复合评分相关。作者认为该成像方法有望作为AD的体内生物标志物。
要点
- AD患者海马11C-UCB-J BPND较认知正常者降低41%(0.87 vs 1.47,P=.005)。
- 部分容积校正后海马SV2A结合降低仍显著(2.15 vs 2.71,P=.02)。
- 海马SV2A结合BPND与情景记忆复合评分相关(R=0.56,P=.01)。
核心结论
- 作者认为这是首个利用11C-UCB-J-PET在体内研究AD突触密度的研究,该方法可能提供突触密度的直接测量,有望作为AD的体内生物标志物及疾病修饰治疗试验的结局指标。
研究设计与样本
- 横断面研究,于2015年11月至2017年6月招募10例AD患者和11例认知正常者,受试者接受11C-UCB-J PET、11C-PiB PET、磁共振成像及认知和神经科评估。
主要发现
- AD患者海马SV2A特异性结合BPND较认知正常者降低41%(认知正常者均值[SD] 1.47[0.37] vs AD患者0.87[0.50],P=.005)。
- 部分容积校正后海马SV2A结合降低仍显著(认知正常者均值[SD] 2.71[0.46] vs AD患者2.15[0.55],P=.02)。
- 海马SV2A特异性结合BPND与总体样本的情景记忆复合评分相关(R=0.56,P=.01)。
- AD患者涵盖从遗忘型轻度认知障碍(n=5)到轻度痴呆(n=5)的疾病阶段,10例(100%)β-淀粉样蛋白阳性;认知正常者11例(100%)β-淀粉样蛋白阴性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Synaptic loss is well established as the major structural correlate of cognitive impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could accelerate the development of disease-modifying treatments for AD. Synaptic vesicle glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses and could serve as a suitable target for synaptic density. OBJECTIVE: To compare hippocampal synaptic vesicle glycoprotein 2A (SV2A) binding in participants with AD and cognitively normal participants using positron emission tomographic (PET) imaging. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study recruited 10 participants with AD and 11 participants who were cognitively normal between November 2015 and June 2017. We hypothesized a reduction in hippocampal SV2A binding in AD, based on the early degeneration of entorhinal cortical cell projections to the hippocampus (via the perforant path) and hippocampal SV2A reductions that had been observed in postmortem studies. Participants underwent high-resolution PET scanning with ((R)-1-((3-(11C-methyl-11C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one), a compound more commonly known as 11C-UCB-J, for SV2A. They also underwent high-resolution PET scanning with carbon 11-labeled Pittsburgh Compound B (11C-PiB) for β-amyloid, magnetic resonance imaging, and cognitive and neurologic evaluation. MAIN OUTCOMES AND MEASURES: Outcomes were 11C-UCB-J-specific binding (binding potential [BPND]) via PET imaging in brain regions of interest in participants with AD and participants who were cognitively normal. RESULTS: Ten participants with AD (5 male and 5 female; mean [SD] age, 72.7 [6.3] years; 10 [100%] β-amyloid positive) were compared with 11 participants who were cognitively normal (5 male and 6 female; mean [SD] age, 72.9 [8.7] years; 11 [100%] β-amyloid negative). Participants with AD spanned the disease stages from amnestic mild cognitive impairment (n = 5) to mild dementia (n = 5). Participants with AD had significant reduction in hippocampal SV2A specific binding (41%) compared with cognitively normal participants, as assessed by 11C-UCB-J-PET BPND (cognitively normal participants: mean [SD] BPND, 1.47 [0.37]; participants with AD: 0.87 [0.50]; P = .005). These reductions remained significant after correction for atrophy (ie, partial volume correction; participants who were cognitively normal: mean [SD], 2.71 [0.46]; participants with AD: 2.15 [0.55]; P = .02). Hippocampal SV2A-specific binding BPND was correlated with a composite episodic memory score in the overall sample (R = 0.56; P = .01). CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first study to investigate synaptic density in vivo in AD using 11C-UCB-J-PET imaging. This approach may provide a direct measure of synaptic density, and it therefore holds promise as an in vivo biomarker for AD and as an outcome measure for trials of disease-modifying therapies, particularly those targeted at the preservation and restoration of synapses.
引用
- Chen MK, Mecca AP, Naganawa M, et al. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol. 2018. PMID: 30014145. doi:10.1001/jamaneurol.2018.1836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。